Back to Trials
NCT07046494PHASE2Recruiting

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder

Rapport Therapeutics Inc.

Start Date

7/25/2025

Completion Date

11/1/2026

Summary

This is a clinical research study for an investigational drug called RAP-219 in participants with bipolar I disorder. This study is being conducted to determine if RAP-219 is safe and effective in participants experiencing mania associated with bipolar I disorder.

Detailed Description

This is a Phase 2, proof-of-concept, multi-center, randomized, double blind, placebo-controlled study designed to evaluate the efficacy, safety and tolerability of RAP-219 in adult participants experiencing mania associated with bipolar I disorder. This is a 3-week inpatient clinical trial.

Eligibility Criteria

Age Range: 18 years to 65 years

Inclusion Criteria: * Meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnosis of bipolar I disorder, with or without psychotic symptoms, as confirmed by the Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT). Episode may contain mixed features, as confirmed by Montgomery-Åsberg Depression Rating Scale (MADRS). * Had at least one prior documented manic episode (with or without psychotic symptoms) that required treatment, within 5 years prior to Visit 1 Exclusion Criteria: * History of any of the following diagnoses: a. schizophrenia; schizoaffective disorder; major depressive disorder; moderate or severe substance or alcohol use disorder; as assessed by the SCID-5-CT b. delirium, dementia, amnestic, or other cognitive disorders; borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorders; by medical history and/or Investigator opinion Note: Any other current diagnoses must be discussed with the Medical Monitor. * Rapid cycler, defined as experiencing ≥4 distinct mood episodes (ie, manic or depressive) each meeting full DSM-5 criteria in the previous 12 months, and each separated by ≥2 months of full or partial remission, or a switch to an episode of the opposite polarity, as assessed by the SCID-5-CT

Interventions

DRUG

RAP-219

OTHER

Placebo

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Bipolar 1 Disorder

Locations

Pillar Clinical Research - Little Rock

Little Rock, Arkansas 72204

United States

Woodland International Research Group

Little Rock, Arkansas 72211

United States

Woodland Research Northwest

Rogers, Arkansas 72758

United States

Inland Psychiatric Medical Group - Chino

Chino, California 91710

United States

Synergy Clinical Research Center - San Diego

Lemon Grove, California 91945

United States

Collaborative Neuroscience Research - Los Alamitos

Los Alamitos, California 90720

United States

NRC Research Institute - Orange

Orange, California 92868

United States

CNRI - San Diego, LLC

San Diego, California 92123

United States

NeuroBehavioral Hospitals of the Palm Beaches - South

Boynton Beach, Florida 33426

United States

United Research Institute

Hialeah, Florida 33012

United States

CenExel - Hollywood

Hollywood, Florida 33024

United States

Segal Trials - Miami Lakes Medical Research Early Phase, Inpatient & Outpatient Site

Miami Lakes, Florida 33016

United States

Neuroscience Research Institute at Ambrosia

West Palm Beach, Florida 33407

United States

CenExel - Decatur

Decatur, Georgia 30030

United States

Pillar Clinical Research - Chicago

Chicago, Illinois 60641

United States

CenExel - Gaithersburg

Gaithersburg, Maryland 20877

United States

Arch Clinical Trials

St Louis, Missouri 63125

United States

Richmond Behavioral Associates

Staten Island, New York 10314

United States

New Hope Clinical Research

Charlotte, North Carolina 28211

United States

Community Clinical Research, Inc.

Austin, Texas 78754

United States

HD Research - Memorial Hermann Village

Houston, Texas 77043

United States

Pillar Clinical Research - Richardson

Richardson, Texas 75080

United States